/
Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ( LN ).
$15.31
$0.65 (-4.07%)
Live · 07:56 PM
37.06% operating margin is above average. ROIC at 14.89%.
Revenue up 20.4% YoY with margins expanding 39.1pp.
Even for strong businesses, today's 7x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
7.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$298M
▲ +20.4% YoY
Net Income (TTM)
$298M
▲ +4893.1% YoY
Op. Margin
41.73%
▲ +39.1pp YoY
ROIC
18.27%
▲ +15.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$167M
▲ +205.6% YoY
Net Debt
$28M
Cash & Equiv.
$41M
5Y CAGR: +41.4%
Continue Research
At a P/E of 7.1, Aurinia Pharmaceuticals (AUPH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aurinia Pharmaceuticals scores 58/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Aurinia Pharmaceuticals scores 58 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 41.7% operating margin and a 18.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AUPH's valuation and scores 58/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.